MX2018000940A - Formulaciones efervescentes de aspartato de ornitina. - Google Patents

Formulaciones efervescentes de aspartato de ornitina.

Info

Publication number
MX2018000940A
MX2018000940A MX2018000940A MX2018000940A MX2018000940A MX 2018000940 A MX2018000940 A MX 2018000940A MX 2018000940 A MX2018000940 A MX 2018000940A MX 2018000940 A MX2018000940 A MX 2018000940A MX 2018000940 A MX2018000940 A MX 2018000940A
Authority
MX
Mexico
Prior art keywords
ornithine aspartate
formulations
ornithine
aspartate
effervescent
Prior art date
Application number
MX2018000940A
Other languages
English (en)
Inventor
Sanjeev Joshi Shraddha
Sharadchandra Guha Ashish
Gadilkar Kedar
Manolikar Mandar
Original Assignee
Evonik Technochemie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Technochemie Gmbh filed Critical Evonik Technochemie Gmbh
Publication of MX2018000940A publication Critical patent/MX2018000940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere al campo de formulaciones farmacéuticas y nutracéuticas y, más específicamente, a formulaciones efervescentes de aspartato de ornitina, así como a los procedimientos para su fabricación. Las formulaciones de aspartato de ornitina de acuerdo con la presente invención comprenden un componente generador de gas, así como un componente ácido que libera dióxido de carbono al contacto con agua. La invención proporciona un proceso simple para la fabricación de tales formulaciones, las cuales son químicamente puras y estables y que exhiben altos niveles de efervescencia. El proceso comprende los siguientes pasos: granulación de una mezcla de aspartato de ornitina, la cual comprende aspartato de ornitina y un componente generador de gas, dando así gránulos G. Al mezclar los componentes de una mezcla final que comprende gránulos G y un componente ácido, se produce una formulación efervescente de aspartato de ornitina.
MX2018000940A 2015-07-24 2016-07-19 Formulaciones efervescentes de aspartato de ornitina. MX2018000940A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3814CH2015 2015-07-24
EP15186592 2015-09-24
PCT/EP2016/067163 WO2017016930A1 (en) 2015-07-24 2016-07-19 Effervescent formulations of ornithine aspartate

Publications (1)

Publication Number Publication Date
MX2018000940A true MX2018000940A (es) 2018-11-09

Family

ID=56550217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000940A MX2018000940A (es) 2015-07-24 2016-07-19 Formulaciones efervescentes de aspartato de ornitina.

Country Status (15)

Country Link
US (1) US20180214372A1 (es)
EP (1) EP3324947B1 (es)
JP (1) JP6851330B2 (es)
KR (1) KR20180030909A (es)
CN (1) CN108024968B (es)
AU (1) AU2016299246B2 (es)
BR (1) BR112018001410A2 (es)
CA (1) CA2991004A1 (es)
DK (1) DK3324947T3 (es)
ES (1) ES2831179T3 (es)
HK (1) HK1254722A1 (es)
MX (1) MX2018000940A (es)
PL (1) PL3324947T3 (es)
RU (1) RU2734417C2 (es)
WO (1) WO2017016930A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022161485A1 (zh) * 2021-01-29 2022-08-04 张曼 一种包含n-乙酰氨基葡萄糖的组合物及其制备方法和应用
WO2023182904A1 (ru) * 2022-03-21 2023-09-28 Акционерное Общество "Производственная Фармацевтическая Компания Обновление" Шипучий лекарственный препарат для приготовления раствора, способ его изготовления
CN114965746B (zh) * 2022-04-24 2023-10-03 扬子江药业集团广州海瑞药业有限公司 门冬氨酸鸟氨酸注射液杂质分析检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3241977A (en) * 1962-01-02 1966-03-22 Gen Foods Corp Effervescent beverage powders
GB965637A (en) * 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
US4093710A (en) * 1976-07-07 1978-06-06 Sandoz, Inc. Rapid dissolving effervescent granules
GB8820327D0 (en) * 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
RU2189228C1 (ru) * 2001-05-24 2002-09-20 Общество с ограниченной ответственностью "Сантэфарм" Фармацевтическая композиция в форме шипучих растворимых таблеток и способ ее получения
US7785640B2 (en) * 2004-01-16 2010-08-31 Amerilab Technologies, Inc. Effervescent composition including cranberry extract
JP2011511797A (ja) * 2008-02-08 2011-04-14 コルゲート・パーモリブ・カンパニー 発泡性組成物
CN102274166A (zh) * 2011-07-13 2011-12-14 辽宁科泰生物基因制药股份有限公司 含有门冬氨酸鸟氨酸的药物组合物
CN103860517A (zh) * 2012-12-18 2014-06-18 北大方正集团有限公司 一种门冬氨酸鸟氨酸泡腾片及其制备工艺
CN103239434A (zh) * 2012-12-26 2013-08-14 辽宁亿灵科创生物医药科技有限公司 门冬氨酸鸟氨酸组合物
CN103960731B (zh) * 2013-01-30 2016-04-27 王玮 一种含门冬氨酸鸟氨酸的饮品及其制备方法
WO2014139469A1 (en) * 2013-03-15 2014-09-18 Wuhan Qr Science And Technology Development Co. Ornithine- or aspartate-containing compositions and the uses thereof

Also Published As

Publication number Publication date
CA2991004A1 (en) 2017-02-02
HK1254722A1 (zh) 2019-07-26
PL3324947T3 (pl) 2021-04-06
ES2831179T3 (es) 2021-06-07
AU2016299246B2 (en) 2021-10-21
CN108024968A (zh) 2018-05-11
JP2018525338A (ja) 2018-09-06
US20180214372A1 (en) 2018-08-02
AU2016299246A1 (en) 2018-01-18
DK3324947T3 (da) 2020-12-14
RU2734417C2 (ru) 2020-10-16
WO2017016930A1 (en) 2017-02-02
EP3324947B1 (en) 2020-09-30
KR20180030909A (ko) 2018-03-26
EP3324947A1 (en) 2018-05-30
BR112018001410A2 (pt) 2018-09-11
RU2018101200A (ru) 2019-07-15
JP6851330B2 (ja) 2021-03-31
CN108024968B (zh) 2022-07-05
RU2018101200A3 (es) 2019-12-23

Similar Documents

Publication Publication Date Title
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
MX2017004896A (es) Uso de hexadeca-8, 15-dienal como producto quimico aromatico.
EP4233843A3 (en) Antibody compositions
MX2019015744A (es) Composiciones farmaceuticas.
MX2017004796A (es) Sistemas y metodos para la sintesis de oxido nitrico.
MX348823B (es) Formulaciones estables de linaclotida.
WO2015082937A3 (en) Composition comprising hydrochlorous acid and uses thereof
EP3686184A3 (en) Ionizable compounds and compositions and uses thereof
CL2016002073A1 (es) Proceso para producir una solución inyectable de noradrenalina de baja concentración estable
MX2018000940A (es) Formulaciones efervescentes de aspartato de ornitina.
MY178714A (en) Aqueous hydrogen peroxide solution for disinfection applications, method for producing same, and disinfection method using same
MX2020001885A (es) Formulaciones de daptomicina.
PH12019500778A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
NZ752750A (en) Stable aqueous capsaicin injectable formulations and medical uses thereof
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
PH12018502581A1 (en) Taste masking formulation for bitter natural compounds
MX2017001177A (es) Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin- 6-ylmetil) imidazo[1,2,b] [1,2,4]triazin-2-il]benzamida.
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
PH12016500414A1 (en) Solid preparation containing choline alfoscerate and method for preparing same
MX370342B (es) Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.
MX371538B (es) Conjugados mezclados de disulfuro de compuestos de tienopiridina y usos de los mismos.
MX2022011564A (es) Tratamiento del dolor.
MX355668B (es) Uso de un extracto de mirto como un agente anti-biopelicula contra propionibacterium acnes.
MX2018010387A (es) Preparacion que contiene esomeprazol.
PH12017501828A1 (en) Stabilized pharmaceutical composition and method for preparing same